Drugs / ATIII-DAF/DI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00319228 | Jan 2006 → Dec 2028 expected | hereditary antithrombin deficiency | Grifols Biologicals, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATIII-DAF/DI | “Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.” NCT00319228 ↗ |
| Modality | Protein / enzyme biologic | “plasma-derived AT-III concentrate” NCT00319228 ↗ |
| Route | Intravenous | “A single dose IV infusion of 50 IU/kg” NCT00319228 ↗ |